ABSTRACTS

P59 Two cases of digestive vasculo-invasive candidiasis in patients with hematological disease

PP03 HLA typing with 11-loci-NGS: benefits in donor selection

PP02 Donor specific anti-HLA antibodies and allogeneic hematopoietic stem cell transplantation

PP01 CRISPR/Cas9 mediated gene correction for the Wiskott-Aldrich syndrome

P67 Analytical interference by dabigatran on Fibrinogen-C XL reagens resulting in spuriously low fibrinogen levels

P66 Adult itp patients treated with romiplostim in daily clinical practice: single center experience

P65 Hospital-acquired thrombocytopenia

P64 Interest of combination of two assays in diagnosis and follow-up of haemophilia A

P63 Tantalum bioactive glasses for hemostasis

P60 Monitoring of wHLA-DR expression in septic patients: feasibility and reproducibility study

PP04 Comparison of bone marrow and umbilical cord derived mesenchymal stromal cells for the treatment of xenogeneic graft-versus-host-disease

P58 A multidisciplinary approach to diagnose X-linked HIGM CD40 ligand deficiency: a case report

P57 Characterization of regulatory T cell (Treg) subsets after allogeneic hematopoietic cell transplantation

P55 Neonatal haemolytic anaemia: a case of common hereditary elliptocytosis

P54 A case of auto-immune haemolytic anemia caused by pembrolizumab and complicated by transient bone marrow aplasia

P53 Phase III clinical trials with amustaline/glutathione (S-303/GSH) pathogen-inactivated RBC

P52 Multicenter evaluation of serologic rbc phenotyping by MDMulticard® (griffols) in patients receiving daratumumab

P51 Contribution of ngs in the diagnosis of Hereditary spherocytosis: case report

P48 Extreme thrombocytosis under azacitidine in a patient with secondary high-risk myelodysplastic syndrome: a case report

PP34 Chromosomal aberrations in chronic myeloid leukemia: response to conventional tyrosine kinase inhibitors and risk of blastic transformation

PP62 Treatment-free remission after TPO receptor agonists in adult itp patients in belgium

PP61 A randomized, double-blind, placebo-controlled, phase 3 study of caplacizumab in patients with acquired thrombotic thrombocytopenic purpura

PP56 Infectious complications of a novel tyrosine kinase inhibitor (ibrutinib) and correlation with immunological markers in patients with malignant hemopathies

PP50 Non-invasive fetal genotyping of RHCE C/c and E alleles in allo-immunized pregnant women: evaluation of a 7-year experience

PP49 Ravulizumab* (ALXN1210) vs eculizumab in complement inhibitor-naive adult patients with PNH

PP37 In vitro investigations of the effect of BCR-ABL tyrosine kinase inhibitors on endothelial cell viability

PP36 In vitro generation of tumor antigen-specific T-cells from healthy donor and patient stem cells

PP35 Efficacy and safety of ponatinib in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) patients in real-world clinical practice: data from a Belgian registry

P47 Blastic plasmacytoid dendritic cell neoplasm: an uncommon CD4±CD5+CD10±CD303-presentation

PP33 miR-15a-5p and miR-21-5p contribute to chemoresistance in acute myeloid leukemia by targeting PDCD4, ARL2 and BTG2

PP17 Targeting of the histone methyltransferases G9a and GLP in multiple myeloma

PP16 Role of interim and end of treatment positron emission tomography for response assessment and prediction of relapse in posttransplant lymphoproliferative disorder

PP15 Development of reticulocytosis through inhibition of terminal erythroid maturation by carfilzomib treatment in multiple myeloma

PP14 MRD analysis by next-generation sequencing in multiple myeloma and pediatric acute lymphoblastic leukemia

PP13 Targeting Protein Arginine Methyltransferase PRMT5 in high-risk multiple myeloma: a new treatment strategy?

PP12 Cognitive impairment, hypoalbuminemia, high CRP level and past history of gastro-intestinal ulcer: 4 markers of frailty which identify older patients with malignant hemopathies who don’t benefit from chemotherapy

PP05 Immune cytopenias after allogeneic hematopoietic stem cell transplantation in children

P09 Stronger impact of centre type compared to activity volume and quality management on the performance of autologous haematopoietic stem cell transplants in adults: report of the belgian transplant registry

P23 Amitryptilin strengthens effects of bortezomib and melphalan treatment in multiple myeloma by inhibiting acid sphingomyelinase

P22 Validation of a single 10-colours tube facilitating discrimination of monoclonal from polyclonal plasma cells in indolent myeloma

P21 Acute hepatitis after chlorambucil alone for chronic lymphocytic leukaemia (CLL)

P20 Contribution of next-generation sequencing analysis to the differential diagnosis of cutaneous lesions suspected of lymphoma

P19 Receptor tyrosine kinase AXL: a potential new target in multiple myeloma

P18 Ibrutinib, the first available BTK inhibitor: single centre experience

P11 Sporadic late-onset nemaline myopathy after allogeneic stem cell transplantation for refractory hepatosplenic gammadelta lymphoma: a case report

P10 Daratumumab administration: good nursing practices

P24 MRD discrepancy during follow-up of p190 BCR-ABL1+ childhood B-ALL: diagnosis of a ‘CML-like’ all subgroup

P08 Neutropenic fever complicating autologous stem cell transplantation in a general hospital: epidemiology and predisposing factors

P07 Immuno-T, 1 year into the motion comic: where we stand, and where we’re heading

P06 Predictive factors and timing of peripheral blood stem cell collection for autologous stem cell transplantation, Leuven, Belgium 2010–2014

06 Erythropoietin modulates red blood cells elimination

05 Overexpression of miR-15a-5p confers chemoresistance by inhibiting autophagy induced by daunorubicin in acute myeloid leukemia cell lines

04 Clofarabine-based consolidation improves relapse-free survival of patients with acute myeloid leukaemia with complex or micro-complex karyotype: results from the randomised alfa-0702 study

03 Renal allograft function following treatment of post-transplant lymphoproliferative disorder

F. Gelders, A. Laenen, A.A. Herelixka, B. Sprangers, D. Dierickx

02 Unravelling the landscape of copy number aberrations in Hodgkin Lymphoma: a joint KU Leuven and Lysa study on circulating cell-free dna

J. Finalet Ferreiro, T. Tousseyn, O. Gheysens, G. Verhoef, M. André, P. Vandenberghe, L. Buedts, L.M. Fornecker, J. Lazarovici, R. Casasnovas, C. Copie, L. Marcelis

P38 Donor and recipient developing JAK2 V617F positive myeloproliferative disease after stem cell transplantation: a case report

P46 Successful treatment with arsenic trioxide and retinoic acid for acute promyelocytic leukaemia in a very elderly patient: a case report

P45 A case report of acute panmyelosis with myelofibosis (APMF) with a distinct molecular pattern

P44 Current routine and beliefs in management of hyperleukocytic acute myeloid leukaemia in multiple belgian centres based on an electronic survey

P43 Contribution of the structural parameters of Sysmex-XN9000 haematology analyser to the differential diagnosis of monocytosis and lymphocytosis in routine laboratory practice

P42 The spectrum of related malignancies

P41 Impact of stopping tyrosine kinase inhibitor therapy on the molecular workload for monitoring: a single centre experience

P40 FIP1L1-PDGFRA P.T674I-D842L: a novel and ponatinib resistant compound mutation in FIP1L1-PDGFRA positive eosinophilic leukaemia

P39 Mutational landscape of 109 MDS and 64 AML patients: a single-centre study

01 A pilot study to assess the feasibility of unrelated umbilical cord blood transplantation with coinfusion of third-party mesenchymal stromal cells after myeloablative or non-myeloablative conditioning in patients with haematological malignancies

A. De Becker, R. Schots, T. Kerre, D. Mazure, J. Maertens, E. Baudoux, C. Lechanteur, Y. Beguin

P32 Belgian registry of breast implant-associated anaplastic large cell lymphoma

P31 HLTV-1 associated adult T cell leukaemia-lymphoma (ATLL) presenting as cutaneous lymphoma: a case report

P30 The identification of actionable genetic events driving disease progression and heterogeneity in peripheral T cell lymphoma, not otherwise specified

P29 Unravelling the molecular landscape of post-transplant diffuse large B cell lymphoma

P28 Occurrence of high grade B-cell lymphoma with rearrangement of MYC and BCL2 and/or BCL6 under ruxolitinib: a case report

P27 PCLO is overexpressed in ETV6-RUNX1-positive B-cell precursor acute lymphoblastic leukaemia

P26 Long-term follow-up of 2 patients treated with Y-rituximab radioimmunotherapy for relapse of predominantly lymphocytic nodular hodgkin’s lymphoma

P25 Comparison of Multigam® IV (5% 10%) in haematological patients with a secondary immunodeficiency to evaluate infusion time, tolerability and satisfaction. A monocentric observational Belgian study